SCHEMBL23210858

SCHEMBL23210858

COc1cc2c(nc1-c1cccc3c1CCC3C#N)c(-c1ccc(Cl)nc1)nn2COCC[Si](C)(C)C

nearest known ligand 0.32

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 8/20 0.32
DGAT1 O75907 2/20 0.31
CD274 Q9NZQ7 2/20 0.30
CHEK1 O14757 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29907161 1.00 S1PR1 (0.32) S1PR1DGAT1CD274CHEK1
SCHEMBL23211014 0.87 DGAT1 (0.30) S1PR1DGAT1
SCHEMBL29907130 0.87 DGAT1 (0.30) S1PR1DGAT1
SCHEMBL23210980 0.86 S1PR1 (0.32) S1PR1
SCHEMBL29907117 0.82 KDM1A (0.36) DGAT1
SCHEMBL23211098 0.82 KDM1A (0.36) DGAT1
SCHEMBL29907115 0.81 DGAT1 (0.35) S1PR1DGAT1CHEK1
SCHEMBL23210803 0.81 DGAT1 (0.35) S1PR1DGAT1CHEK1
SCHEMBL23264044 0.77 CHEK1 (0.41) S1PR1CHEK1
SCHEMBL30308806 0.77 TBK1 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250057852-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2025-02-20 US disclosed
US-12083124-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2024-09-10 US disclosed
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2023-10-26 US disclosed
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2023-10-26 US disclosed
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2023-10-26 US disclosed
CN-115835908-A Bicyclic heterocycles as FGFR inhibitors 因赛特公司 2023-03-21 CN disclosed
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2023-03-21 US disclosed
EP-4045151-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS Incyte Corporation (US) 2022-08-24 EP disclosed
WO-2021076602-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2021-04-22 WO disclosed
WO-2021076602-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2021-04-22 WO disclosed
US-20210106588-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2021-04-15 US disclosed
US-20210106588-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2021-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12083124-B2 Bicyclic heterocycles as FGFR inhibitors FGFR1, FGFR3, FGFR2 S1PR1 3409/4885DGAT1 2962/4885CD274 422/4885
US-20210106588-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 S1PR1 3409/4885DGAT1 2962/4885CD274 422/4885
US-20250057852-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 S1PR1 3409/4885DGAT1 2962/4885CD274 422/4885
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors FGFR1, FGFR3, FGFR2 S1PR1 3409/4885DGAT1 2962/4885CD274 422/4885
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 S1PR1 3409/4885DGAT1 2962/4885CD274 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.